PE20110028A1 - Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato - Google Patents
Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamatoInfo
- Publication number
- PE20110028A1 PE20110028A1 PE2010001111A PE2010001111A PE20110028A1 PE 20110028 A1 PE20110028 A1 PE 20110028A1 PE 2010001111 A PE2010001111 A PE 2010001111A PE 2010001111 A PE2010001111 A PE 2010001111A PE 20110028 A1 PE20110028 A1 PE 20110028A1
- Authority
- PE
- Peru
- Prior art keywords
- isoxazole
- dihydro
- chloro
- alkyl
- metabotropic glutamate
- Prior art date
Links
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title abstract 3
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title abstract 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical class C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003623 enhancer Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 PYRROLIDINE-1-CARBONYL Chemical class 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/08—Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound
- A61B17/083—Clips, e.g. resilient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/08—Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound
- A61B17/085—Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound with adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/10—Surgical instruments, devices or methods for applying or removing wound clamps, e.g. containing only one clamp or staple; Wound clamp magazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/10—Surgical instruments, devices or methods for applying or removing wound clamps, e.g. containing only one clamp or staple; Wound clamp magazines
- A61B17/105—Wound clamp magazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5948508P | 2008-06-06 | 2008-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110028A1 true PE20110028A1 (es) | 2011-02-11 |
Family
ID=41398335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2010001111A PE20110028A1 (es) | 2008-06-06 | 2009-06-08 | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato |
Country Status (40)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | ļ¼ļ¼ļ¼-äŗå代ä¹ļ¼-ę°°åŗ-å”å¶é ®č”ēē©åå ¶ä½ēŗļ½ļ¼§ļ½ļ½ļ¼²ļ¼-åé«ä¹ę£åē°ä½ę§čŖæēÆåä¹ēØé |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| WO2009033703A1 (en) | 2007-09-14 | 2009-03-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones |
| TWI475995B (zh) | 2007-09-14 | 2015-03-11 | č©¹ę£®č„ē©å ¬åø | ļ¼āļ¼ļ¼āļ¼äŗå代ļ¼ļ¼ļ¼čÆåŗļ¼ļ¼ļ¼ļ¼ļ¼ļ¼ļ¼ļ¼ļ¼åę°«ļ¼ļ¼ļ½ļ¼ļ¼āļ½ļ¼ćļ¼ļ¼ļ¼āćčÆå”å¶åŗļ¼ļ¼āļ¼é ®åē© |
| US7790760B2 (en) * | 2008-06-06 | 2010-09-07 | Astrazeneca Ab | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286 |
| MX2011002042A (es) | 2008-09-02 | 2011-06-20 | Ortho Mcneil Janssen Pharm | Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico. |
| MX2011003691A (es) | 2008-10-16 | 2011-09-06 | Ortho Mcneil Janssen Pharm | Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico. |
| AR076859A1 (es) | 2009-05-12 | 2011-07-13 | Ortho Mcneil Janssen Pharm | Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. |
| NZ596078A (en) | 2009-05-12 | 2013-06-28 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ćøć¤ć³ć»ć³ć»ćć¢ć¼ćć·ć¦ć¼ćć«ć«ćŗć»ć¤ć³ć³ć¼ćć¬ć¼ććć | ļ¼ļ¼ļ¼ļ¼ļ¼āććŖć¢ć¾ćļ¼»ļ¼ļ¼ļ¼āļ½ļ¼½ććŖćøć³čŖå°ä½ććć³ļ½ļ¼§ļ½ļ½ļ¼²ļ¼å容ä½ć®ććøćć£ćć¢ćć¹ććŖććÆć¢ćøć„ć¬ć¼ćæć¼ćØćć¦ć®ćććć®ä½æēØ |
| WO2012062751A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| CN103298810B (zh) | 2010-11-08 | 2016-03-16 | ęØę£®å¶čÆå ¬åø | 1,2,4-äøå并[4,3-a]å”å¶č”ēē©åå ¶ä½äøŗMGLUR2åä½ēę£åęč°čåēēØé |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | Ł Ų±ŁŲØŲ§ŲŖ 6Ų 7- Ų«Ų§ŁŁ ŁŁŲÆŲ±Ł ŲØŁŲ±Ų§Ų²ŁŁŁ [5Ų1-a] ŲØŁŲ±Ų§Ų²ŁŁ- 4 (5 ŁŲÆ)- Ų§ŁŁ ŁŲ§Ų³ŲŖŲ®ŲÆŲ§Ł ŁŲ§ ŲØŲµŁŲ© Ł ŁŲøŁ Ų§ŲŖ ŲŖŁŲ§Ų±ŲŗŁŲ© Ų³ŁŲØŁŲ© ŁŁ Ų³ŲŖŁŲØŁŲ§ŲŖ Ł ŁŲ¬ŁŁŲ± 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | Ł Ų±ŁŲØŲ§ŲŖ 2Ų1Ų 4- Ų«ŁŲ§Ų«Ł Ų²ŁŁŁ [3Ų4-a] ŲØŁŲ±ŁŲÆŁŁ ŁŲ§Ų³ŲŖŲ®ŲÆŲ§Ł ŁŲ§ ŲØŲµŁŲ© Ł ŁŲøŁ Ų§ŲŖ ŲŖŁŲ§Ų±ŲŗŁŲ© Ł ŁŲ¬ŲØŲ© ŁŁ Ų³ŲŖŁŲØŁŲ§ŲŖ Ł ŁŲ¬ŁŁŲ± 2 |
| CN109999025A (zh) | 2014-01-21 | 2019-07-12 | č©¹ę£®čÆäøęéå ¬åø | å ę¬ä»£č°¢åč°·ę°Øé øč½åä½äŗå2ēę£å«ęč°čē©ęę£ä½ęæåØåēē»ååå ¶ēØé |
| IL279202B2 (en) | 2014-01-21 | 2023-09-01 | Janssen Pharmaceutica Nv | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use |
| US10099993B2 (en) | 2014-04-06 | 2018-10-16 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof |
| KR101663662B1 (ko) * | 2015-06-17 | 2016-10-14 | ķźµź³¼ķźø°ģ ģ°źµ¬ģ | ėģ¬ģ± źøė£Øķė©ģ“ķø ģģ©ģ²“ 1ģ ķģ±ģ ģ§ė ģ ź· ģė¦“ ģģ“ģģ„ģ¬ģ”ø ģ ėģ²“ |
| WO2017089892A1 (en) * | 2015-11-25 | 2017-06-01 | Astrazeneca Ab | Deuterated isoxazole derivatives and their use as metabotropic glutamate receptor potentiators |
| US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
| US11078204B2 (en) | 2018-11-13 | 2021-08-03 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
| WO2020102216A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Substituted heterocyclic derivatives as pi3k inhibitors |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE620654C (de) | 1933-04-29 | 1935-10-24 | Smith & Sons Ltd S | Geschwindigkeitsanzeiger |
| US3993617A (en) * | 1975-10-30 | 1976-11-23 | Morton-Norwich Products, Inc. | Antifungal 2-substituted phthalimidines |
| US5175157A (en) * | 1985-11-27 | 1992-12-29 | Boehringer Ingelheim Gmbh | Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them |
| WO1992017448A1 (fr) | 1991-04-01 | 1992-10-15 | Kyowa Hakko Kogyo Co., Ltd. | Derive de 3-methylenisoindolin-1-one |
| TW219935B (enExample) | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| EP0602814A1 (en) | 1992-12-18 | 1994-06-22 | Takeda Chemical Industries, Ltd. | Crystal forms of optically active isoindolines and their use |
| US5681954A (en) * | 1993-05-14 | 1997-10-28 | Daiichi Pharmaceutical Co., Ltd. | Piperazine derivatives |
| US6017919A (en) * | 1996-02-06 | 2000-01-25 | Japan Tobacco Inc. | Compounds and pharmaceutical use thereof |
| AU7548298A (en) | 1997-05-30 | 1998-12-30 | Meiji Seika Kaisha Ltd. | Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same |
| CA2311131A1 (en) | 1997-11-21 | 1999-06-03 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
| CA2401711C (en) * | 2000-02-29 | 2008-06-03 | Mitsubishi Pharma Corporation | Cyclic amide derivatives |
| BR0112856A (pt) | 2000-07-31 | 2003-07-01 | Smithkline Beecham Plc | MĆ©todo para o tratamento dos distĆŗrbios, composto ou um sal ou solvato deste, processo para a preparaĆ§Ć£o dos mesmos, composiĆ§Ć£o farmacĆŖutico, mĆ©todo de tratamento e/ou profilaxia de um ou mais dos distĆŗrbios, uso de um composto, e, mĆ©todo para o tratamento de diabetes, grande depressĆ£o, depressĆ£o manƬaca, ansiedade, esquizofrenia e distĆŗrbios do sono, em mamƬferos humanos e nĆ£o humanos |
| PL368129A1 (en) | 2001-08-09 | 2005-03-21 | Ono Pharmaceutical Co, Ltd. | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| WO2003087044A2 (en) | 2002-04-09 | 2003-10-23 | 7Tm Pharma A/S | Novel carboxamide compounds for use in mch receptor related disorders |
| FR2840302B1 (fr) | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| DE10238865A1 (de) | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue CarbonsƤureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| GB0223232D0 (en) | 2002-10-07 | 2002-11-13 | Pfizer Ltd | Chemical compounds |
| CA2519954A1 (en) | 2003-03-26 | 2004-10-14 | Merck & Co., Inc. | Benzamide modulators of metabotropic glutamate receptors |
| GB0308025D0 (en) | 2003-04-07 | 2003-05-14 | Glaxo Group Ltd | Compounds |
| US7129260B2 (en) * | 2003-06-02 | 2006-10-31 | Abbott Laboratories | Isoindolinone kinase inhibitors |
| US20070135485A1 (en) | 2003-10-22 | 2007-06-14 | Gillig James R | Novel mch receptor antagonists |
| WO2005074643A2 (en) | 2004-01-30 | 2005-08-18 | Smithkline Beecham Corporation | Benzamide compounds useful as rock inhibitors |
| JP2007523183A (ja) | 2004-02-18 | 2007-08-16 | ć¢ć¹ćć©ć¼ćć« ć¢ćÆććć©ć° | ēø®åč¤ē“ ē°å¼ååē©åć³ä»£č¬čŖæēÆåć°ć«ćæćć³é øå容ä½ć¢ć³ćæć“ćć¹ććØćć¦ć®ćć®ä½æēØ |
| KR101197482B1 (ko) | 2004-03-05 | 2012-11-09 | ėģ° ź°ź°ģæ ź³ źµ ź°ė¶ģķ¤ ź°ģ“ģ¤ | ģ“ģģ¬ģ”øė¦° ģ¹ķ ė²¤ģ¦ģėÆøė ķķ©ė¬¼ ė° ģ ķ“ģė¬¼ ė°©ģ ģ |
| CA2558278A1 (en) | 2004-03-05 | 2005-09-15 | Banyu Pharmaceutical Co., Ltd. | Diaryl-substituted five-membered heterocycle derivative |
| SE0400970D0 (sv) | 2004-04-14 | 2004-04-14 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| TW200613272A (en) * | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| JP2008517920A (ja) | 2004-10-25 | 2008-05-29 | ć”ć«ćÆ ćØć³ć ć«ć ććć¼ ć¤ć³ć³ć¼ćć¬ć¼ććć | 代č¬čŖæēÆåć°ć«ćæćć³é øå容ä½ć®č¤ē“ ē°å¼ć¤ć³ććć³å¢å¼·å å |
| AU2006216917A1 (en) | 2005-02-24 | 2006-08-31 | Merck Sharp & Dohme Corp. | Benzazole potentiators of metabotropic glutamate receptors |
| EP1893606A2 (en) | 2005-05-18 | 2008-03-05 | Addex Pharma SA | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| GB0510142D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| TW200728277A (en) | 2005-06-29 | 2007-08-01 | Palau Pharma Sa | Bicyclic derivatives as P38 inhibitors |
| EP1912939A1 (en) * | 2005-08-12 | 2008-04-23 | AstraZeneca AB | Metabotropic glutamate-receptor-potentiating isoindolones |
| US7868008B2 (en) | 2005-08-12 | 2011-01-11 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
| US7807706B2 (en) * | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
| BRPI0616571A2 (pt) | 2005-09-27 | 2011-06-21 | Hoffmann La Roche | oxadiazolil pirazol-piridiminas como antagonistas de mglur2, processo para sua preparaĆ§Ć£o, composiĆ§Ć£o farmacĆŖutica que os contĆ©m e uso dos mesmo |
| TW200804281A (en) | 2006-02-16 | 2008-01-16 | Astrazeneca Ab | New metabotropic glutamate receptor-potentiating isoindolones |
| TW200911255A (en) * | 2007-06-07 | 2009-03-16 | Astrazeneca Ab | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 |
| TWI417100B (zh) * | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | ļäŗåč”ēē©åå ¶ä½ēŗ代č¬åéŗ©čŗé øåé«å¢ęå-ļ¼ļ¼ļ¼ä¹ēØé |
| US7790760B2 (en) * | 2008-06-06 | 2010-09-07 | Astrazeneca Ab | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286 |
-
2009
- 2009-06-03 US US12/477,347 patent/US7790760B2/en not_active Expired - Fee Related
- 2009-06-03 SA SA109300358A patent/SA109300358B1/ar unknown
- 2009-06-04 TW TW103145569A patent/TW201514173A/zh unknown
- 2009-06-04 TW TW098118593A patent/TWI382027B/zh not_active IP Right Cessation
- 2009-06-04 TW TW101129417A patent/TWI477499B/zh not_active IP Right Cessation
- 2009-06-05 AR ARP090102031A patent/AR072016A1/es unknown
- 2009-06-05 UY UY0001031870A patent/UY31870A/es not_active Application Discontinuation
- 2009-06-08 CA CA2726925A patent/CA2726925A1/en not_active Abandoned
- 2009-06-08 BR BRPI0913585A patent/BRPI0913585A2/pt not_active IP Right Cessation
- 2009-06-08 EP EP09758630.9A patent/EP2303872B1/en active Active
- 2009-06-08 UA UAA201014034A patent/UA107649C2/uk unknown
- 2009-06-08 PL PL09758630T patent/PL2303872T3/pl unknown
- 2009-06-08 AU AU2009255784A patent/AU2009255784B2/en not_active Ceased
- 2009-06-08 SI SI200930928T patent/SI2303872T1/sl unknown
- 2009-06-08 CN CN200980129149.7A patent/CN102105466B/zh not_active Expired - Fee Related
- 2009-06-08 MY MYPI2010005780A patent/MY156552A/en unknown
- 2009-06-08 EA EA201300342A patent/EA201300342A1/ru unknown
- 2009-06-08 RS RS20140295A patent/RS53392B/sr unknown
- 2009-06-08 NZ NZ590344A patent/NZ590344A/en not_active IP Right Cessation
- 2009-06-08 PE PE2010001111A patent/PE20110028A1/es not_active Application Discontinuation
- 2009-06-08 MX MX2010012949A patent/MX2010012949A/es active IP Right Grant
- 2009-06-08 PT PT97586309T patent/PT2303872E/pt unknown
- 2009-06-08 WO PCT/SE2009/050682 patent/WO2009148403A1/en not_active Ceased
- 2009-06-08 EA EA201001724A patent/EA018412B1/ru not_active IP Right Cessation
- 2009-06-08 ES ES09758630.9T patent/ES2469837T3/es active Active
- 2009-06-08 KR KR1020107027224A patent/KR20110020797A/ko not_active Abandoned
- 2009-06-08 DK DK09758630.9T patent/DK2303872T3/da active
- 2009-06-08 JP JP2011512416A patent/JP5476371B2/ja not_active Expired - Fee Related
- 2009-06-08 HR HRP20140451AT patent/HRP20140451T1/hr unknown
- 2009-06-08 EP EP14164664.6A patent/EP2772492B1/en active Active
- 2009-10-08 US US12/575,891 patent/US7781434B2/en not_active Expired - Fee Related
-
2010
- 2010-08-13 NI NI201000209A patent/NI201000209A/es unknown
- 2010-08-20 US US12/860,330 patent/US8148372B2/en not_active Expired - Fee Related
- 2010-08-26 US US12/869,263 patent/US7888353B2/en not_active Expired - Fee Related
- 2010-11-26 CO CO10149429A patent/CO6321239A2/es active IP Right Grant
- 2010-11-29 IL IL209622A patent/IL209622A0/en unknown
- 2010-11-30 ZA ZA2010/08611A patent/ZA201008611B/en unknown
- 2010-12-03 CL CL2010001348A patent/CL2010001348A1/es unknown
- 2010-12-06 SV SV2010003751A patent/SV2010003751A/es not_active Application Discontinuation
- 2010-12-06 NI NI2010002092A patent/NI201002092A/es unknown
- 2010-12-06 NI NI2010002091A patent/NI201002091A/es unknown
- 2010-12-06 GT GT201000342A patent/GT201000342A/es unknown
- 2010-12-06 CU CU20100238A patent/CU23883B1/es not_active IP Right Cessation
- 2010-12-06 HN HN2010002582A patent/HN2010002582A/es unknown
- 2010-12-06 CR CR11826A patent/CR11826A/es unknown
- 2010-12-06 DO DO2010000375A patent/DOP2010000375A/es unknown
- 2010-12-07 EC EC2010010662A patent/ECSP10010662A/es unknown
-
2014
- 2014-02-06 JP JP2014020956A patent/JP5815765B2/ja not_active Expired - Fee Related
- 2014-06-11 CY CY20141100416T patent/CY1115301T1/el unknown
-
2015
- 2015-02-13 HK HK15101607.6A patent/HK1201255A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
| CO6300954A2 (es) | Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk | |
| PE20090884A1 (es) | Compuestos de indol como activadores de glucoquinasa | |
| PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
| PE20091724A1 (es) | Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7 | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| PE20081229A1 (es) | Antagonistas de receptor de orexina de diazepam sustituido | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| PE20141228A1 (es) | Derivados de pirrolopirimidina y purina | |
| PE20140207A1 (es) | Composiciones y metodos para modular el fxr | |
| PE20121158A1 (es) | Derivados de feniletinilo como moduladores alostericos positivos (map) | |
| PE20070585A1 (es) | Derivados de sulfonamida como activadores de glucoquinasa | |
| PE20081800A1 (es) | NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA | |
| PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
| PE20080150A1 (es) | Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch) | |
| PE20110852A1 (es) | Antagonistas del receptor de orexina de isonicotinamida | |
| ECSP10010654A (es) | Derivados de tienopiridonas como activadores de proteĆna quinasa activados por amp (ampk) | |
| DOP2007000018A (es) | Moduladores de indol sulfonamida de receptores de progesterona | |
| PE20120561A1 (es) | Compuestos que modulan selectivamente el receptor cb2 | |
| PE20071156A1 (es) | COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA) | |
| PE20140934A1 (es) | Derivados de pirazol | |
| PE20110196A1 (es) | 5-alquinil-pirimidinas | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| PE20081753A1 (es) | Compuestos y composiciones como inhibidores de la proteasa activadora de canal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |